Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Thursday, April 16th | 2pm ET / 11am PT | Presented By: BBK Worldwide
BBK Worldwide hosts a webinar exploring this new connected health model and its impact on clinical research. Join their expert panel, which includes mHealth experts from BBK Worldwide, Oracle and Empatica, and learn key strategies for successful implementation. Registration is free – click here.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!